Sideroblastic anemia historical perspective: Difference between revisions

Jump to navigation Jump to search
m (Template)
Line 8: Line 8:


==Historical Perspective==
==Historical Perspective==
=== Discovery ===
X-linked sideroblastic anemia was first described by Cooley (1945), a Detroit pediatrician-hematologist He pointed out possible X-linkage in a family in which 19 males in 5 generations were affected, with transmission through unaffected females.
Rundles and Falls (1946) reported 2 families, . Somewhat enlarged spleens and minor red cell abnormalities without anemia were observed in female carriers. Pyridoxine responsiveness was demonstrated in at least 2 affected members of Rundles and Falls' family
Byrd and Cooper (1961) referred to the disorder as hereditary iron-loading anemia
Peto et al. (1983) focused attention on iron overload in mild sideroblastic anemia after the death from cardiac iron loading of a middle-aged woman with a very mild form of familial sideroblastic anemia.
Cotter et al. (1995) described a previously unaffected 81-year-old woman in whom microcytic sideroblastic anemia developed. The initial diagnosis was myelodysplastic syndrome, but the recognition of the X-linked congenital sideroblastic anemia allowed successful treatment with pyridoxine. She was found to be heterozygous for a point mutation of the ALAS2 gene
Aivado et al. (2006) reported a family in which a mother and her 2 daughters had pyridoxine-unresponsive sideroblastic anemia confirmed by genetic analysis. The disorder was variable in severity and X-chromosome inactivation studies were done.
Hines (1971) observed decreased levels of pyridoxal phosphokinase in red cells and livers of patients with pyridoxine-dependent refractory sideroblastic anemia.
Aoki et al. (1973) found deficiency of delta-aminolevulinic acid synthetase in the red cells of patients with sideroblastic anemia, some of whom were males with congenital anemia which in some responded to treatment with B6.
Recently, it has been proposed that iron accumulates within mitochondrial ferritin (Levi ''et al'', 2001
== Outbreaks[edit | edit source] ==
There have been several outbreaks of [disease name], which are summarized below:
== Landmark Events in the Development of Treatment Strategies[edit | edit source] ==
In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].
== Impact on Cultural History[edit | edit source] ==
== Famous Cases ==


==References==
==References==

Revision as of 20:18, 8 August 2018

Sideroblastic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sideroblastic Anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sideroblastic anemia historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sideroblastic anemia historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sideroblastic anemia historical perspective

CDC on Sideroblastic anemia historical perspective

Sideroblastic anemia historical perspective in the news

Blogs on Sideroblastic anemia historical perspective

Directions to Hospitals Treating Sideroblastic anemia

Risk calculators and risk factors for Sideroblastic anemia historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Historical Perspective

Discovery

X-linked sideroblastic anemia was first described by Cooley (1945), a Detroit pediatrician-hematologist He pointed out possible X-linkage in a family in which 19 males in 5 generations were affected, with transmission through unaffected females.

Rundles and Falls (1946) reported 2 families, . Somewhat enlarged spleens and minor red cell abnormalities without anemia were observed in female carriers. Pyridoxine responsiveness was demonstrated in at least 2 affected members of Rundles and Falls' family

Byrd and Cooper (1961) referred to the disorder as hereditary iron-loading anemia

Peto et al. (1983) focused attention on iron overload in mild sideroblastic anemia after the death from cardiac iron loading of a middle-aged woman with a very mild form of familial sideroblastic anemia.

Cotter et al. (1995) described a previously unaffected 81-year-old woman in whom microcytic sideroblastic anemia developed. The initial diagnosis was myelodysplastic syndrome, but the recognition of the X-linked congenital sideroblastic anemia allowed successful treatment with pyridoxine. She was found to be heterozygous for a point mutation of the ALAS2 gene

Aivado et al. (2006) reported a family in which a mother and her 2 daughters had pyridoxine-unresponsive sideroblastic anemia confirmed by genetic analysis. The disorder was variable in severity and X-chromosome inactivation studies were done.

Hines (1971) observed decreased levels of pyridoxal phosphokinase in red cells and livers of patients with pyridoxine-dependent refractory sideroblastic anemia.

Aoki et al. (1973) found deficiency of delta-aminolevulinic acid synthetase in the red cells of patients with sideroblastic anemia, some of whom were males with congenital anemia which in some responded to treatment with B6.

Recently, it has been proposed that iron accumulates within mitochondrial ferritin (Levi et al, 2001

Outbreaks[edit | edit source]

There have been several outbreaks of [disease name], which are summarized below:

Landmark Events in the Development of Treatment Strategies[edit | edit source]

In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].

Impact on Cultural History[edit | edit source]

Famous Cases

References

Template:WH Template:WS